EUVIMEDEUVIMED entdecken
Crossref

Fatal Outcome in Chronic Lymphocytic Leukemia with Extreme Leukocytosis: Nemtabrutinib-İnduced Rash, Acute Myocardial İnfarction, and Unsuccessful Leukapheresis

Fikriye Esra Gurses Ulubay, Engin Kelkitli, Mehmet Turgut

AMERICAN JOURNAL OF CASE REPORTS AND CLINICAL IMAGES · 2025

DOI: 10.51521/ajcrci.2025.e22.142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AMERICAN JOURNAL OF CASE REPORTS AND CLINICAL IMAGES, 2025. Verfasst von Fikriye Esra Gurses Ulubay und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic lymphocytic leukemia [CLL] is usually indolent, but patients with ex- treme leukocytosis and delayed therapy may develop catastrophic complications. Novel non-co- valent Bruton tyrosine kinase [BTK] inhibitors, such as nemtabrutinib, show promise, but their real-world toxicity profile is not fully defined. Case Presentation: We report a 62-year-old female diagnosed with CLL in May 2025 [TP53 wild-type, normal 17p]. Due to social factors, she delayed therapy until July 2025, presenting with WBC 449 × 109/L, anemia, thrombocytopenia, hepatosplenomegaly, and disseminated lymphadenopathy. Nemtabrutinib [65 mg/day] was started on August 12, 2025, within a clinical trial. On day 12, she developed a diffuse erythematous rash, which resolved rapidly with systemic corticosteroids [prednisolone 60 mg/day, tapered weekly]. Therapy was withheld. On day 23, she presented with acute myocardial infarction [99% LAD stenosis], and concurrent WBC had increased to 894 x 109/L. Leukapheresis was attempted for hyperviscosity risk but could not be completed due to refractory hypotension in the context of recent angioplasty. Despite intensive care, the patient died 21 hours later from cardiac arrest.

Conclusion

This case highlights the lethal interaction of extreme leukocytosis, cardiovascular complications, and novel BTK inhibitor toxicity. To our knowledge, this is the first report of nemta- brutinib-associated rash followed by fatal cardiovascular deterioration in CLL. Early intervention, vigilant toxicity monitoring, and individualized supportive care are crucial in high-risk patients. K E Y W O R D S: Chronic lymphocytic leukemia, Nemtabrutinib, Leukocytosis, Leukapheresis, Myocardial infarction, References 1. Hallek M. Chronic Lymphocytic Leukemia: 2025 Update on the Ep- idemiology, Pathogenesis, Diagnosis, and Therapy. Am J Hematol. 2025;100[3]:450-80. 2. Burger JA. Bruton Tyrosine Kinase Inhibitors: Present and Future. Can- cer J. 2019;25[6]:386-93. 3. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine ki- nase in B cells and malignancies. Mol Cancer. 2018;17[1]:57. 4. Quartermaine C, Ghazi SM, Yasin A, Awan FT, Fradley M, Wiczer T, et al. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC Cardio- Oncol. 2023;5[5]:570-90. 5. Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, et al. First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma. Cancer Discov. 2024;14[1]:66-75. 6. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocyto- sis, leukostasis and leukapheresis: practice management. Blood Rev. 2012;26[3]:117-22. 7. Singh N, Singh Lubana S, Dabrowski L, Sidhu G. Leukostasis in Chronic Lymphocytic Leukemia. Am J Case Rep. 2020;21:e924798. 8. Lichtman MA, Rowe JM. Hyperleukocytic leukemias: rheological, clini- cal, and therapeutic considerations. Blood. 1982;60[2]:279-83. 9. Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Advances. 2024;8[9]:2300-9. 10. Vallabhaneni S, Adusumalli S, Wu J, Groeneveld PW, Gerson J, O'Quinn RP. Cardiotoxicity from bruton tyrosine kinase inhibitors [BTKi]-an analysis of an administrative health claims database. Cardiooncology. 2024;10[1]:33. 11. Boriani G, Menna P, Morgagni R, Minotti G, Vitolo M. Ibrutinib and Bru- ton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death. Chemotherapy. 2023;68[2]:61-72. 12. Cukierman T, Gatt ME, Libster D, Goldschmidt N, Matzner Y. Chron- ic lymphocytic leukemia presenting with extreme hyperleukocyto- sis and thrombosis of the common femoral vein. Leuk Lymphoma. 2002;43[9]:1865-8.

Zitieren

APA

Ulubay, F. E. G., Kelkitli, E., & Turgut, M. (2025). Fatal Outcome in Chronic Lymphocytic Leukemia with Extreme Leukocytosis: Nemtabrutinib-İnduced Rash, Acute Myocardial İnfarction, and Unsuccessful Leukapheresis. AMERICAN JOURNAL OF CASE REPORTS AND CLINICAL IMAGES. https://doi.org/10.51521/ajcrci.2025.e22.142

Vancouver

Ulubay FEG, Kelkitli E, Turgut M. Fatal Outcome in Chronic Lymphocytic Leukemia with Extreme Leukocytosis: Nemtabrutinib-İnduced Rash, Acute Myocardial İnfarction, and Unsuccessful Leukapheresis. AMERICAN JOURNAL OF CASE REPORTS AND CLINICAL IMAGES. 2025. doi:10.51521/ajcrci.2025.e22.142

BibTeX
@article{Ulubay2025,
  author = {Ulubay, Fikriye Esra Gurses and Kelkitli, Engin and Turgut, Mehmet},
  title = {Fatal Outcome in Chronic Lymphocytic Leukemia with Extreme Leukocytosis: Nemtabrutinib-İnduced Rash, Acute Myocardial İnfarction, and Unsuccessful Leukapheresis},
  journal = {AMERICAN JOURNAL OF CASE REPORTS AND CLINICAL IMAGES},
  year = {2025},
  doi = {10.51521/ajcrci.2025.e22.142}
}
Kostenlos starten →